EGFR and non-small cell lung carcinoma: Earlier studies showed that MET-amplification, at least in part, causes resistance to 1G EGFR-TKIs in NSCLC by activating ERBB3 signaling, which could be mediated by a strong direct interaction of MET with ERBB3 [137,167].